1. P. Greenwald, From carcinogenesis to clinical interventions for cancer prevention. Toxicology
166, 37–45 (2001).
2. G. J. Kelloff, J. A. Crowell, V. E. Steele, R. A. Lubet, W. A. Malone, C. W. Boone, L. Kopelovich, E. T. Hawk, R. Lieberman, J. A. Lawrence, et al., Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr
130, 467S–471S (2000).
3. Y.-J. Surh, Cancer chemoprevention with dietary phytochemicals. Nature Rev Cancer
3, 768–780 (2003).
4. A. H. Conney, T. Lysz, T. Ferraro, T. F. Abidi, P. S. Manchand, J. D. Laskin, and M. T. Huang, Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul
31, 385–396 (1991).
5. A. Duvoix, R. Blasius, S. Delhalles, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato, M. and M. Diederich, Chemopreventive and therapeutic effects of curcumin. Cancer Lett
223, 181–190 (2005).
6. M. T. Huang, Z. Y. Wang, C. A. Georgiadis, J. D. Laskin, and A. H. Conney, Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis
13, 2183–2186 (1992).
7. M. Nagabhushan and S. V. Bhide, Curcumin as an inhibitor of cancer. J Am Coll Nutr
8. L. A. Cohen, A review of animal model studies of tomato carotenoids, lycopene, and cancer chemoprevention. Exp Biol Med (Maywood)
227, 864–868 (2002).
9. S. Das, S. Banerjee, and P. Saha, The models for assessment of chemopreventive agents: single organ models. Asian Pac J Cancer Prev
5, 15–23 (2004).
10. J. DiGiovanni, Multistage carcinogenesis in mouse skin. Pharmacol Ther
54, 63–128 (1992).
11. M. T. Huang, Y. R. Lou, J. G. Xie, W. Ma, Y. P. Lu, P. Yen, B. T. Zhu, H. Newmark, and C. T. Ho, Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis
19, 1697–1700 (1998).
12. M. T. Huang, W. Ma, P. Yen, J. G. Xie, J. Han, K. Frenkel, D. Grunberger, and A. H. Conney, Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis
18, 83–88 (1997).
13. M. T. Huang, W. Ma, Y. P. Lu, R. L. Chang, C. Fisher, P. S. Manchand, H. L. Newmark, and A. H. Conney, Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis
16, 2493–2497 (1995).
14. M. A. Azuine and S. V. Bhide, Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer
17, 77–83 (1992).
15. M. A. Pereira, S. L. Herren-Freund, A. L. Britt, and M. M. Khoury, Effect of coadministration of phenobarbital sodium on N-nitrosodiethylamine-induced gamma-glutamyltransferase-positive foci and hepatocellular carcinoma in rats. J Natl Cancer Inst
72, 741–744 (1984).
16. M. Sreepriya and G. Bali, Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Fitoterapia
76, 549–555 (2005).
17. S. E. Chuang, M. L. Kuo, C. H. Hsu, C. R. Chen, J. K. Lin, G. M. Lai, C. Y. Hsieh, and A. L. Cheng, Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis
21, 331–335 (2000).
18. S. Busquets, N. Carbo, V. Almendro, M. T. Quiles, F. J. Lopez-Soriano, and J. M. Argiles, Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett
167, 33–38 (2001).
19. M. B. Thompson, The Min mouse: A genetic model for intestinal carcinogenesis. Toxicol Pathol
25, 329–332 (1997).
20. A. R. Moser, C. Luongo, K. A. Gould, M. K. McNeley, A. R. Shoemaker, and W. F. Dove, ApcMin:A mouse model for intestinal and mammary tumorigenesis. Eur J Cancer
31A, 1061–1064 (1995).
21. D. E. Corpet and F. Pierre, Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev
12, 391–400 (2003).
22. S. Perkins, R. D. Verschoyle, K. Hill, I. Parveen, M. D. Threadgill, R. A. Sharma, M. L. Williams, W. P. Steward, and A. J. Gescher, Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev
11, 535–540 (2002).
23. N. N. Mahmoud, A. M. Carothers, D. Grunberger, R. T. Bilinski, M. R. Churchill, C. Martucci, H. L. Newmark, and M. M. Bertagnolli, Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis
21, 921–927 (2000).
24. M. T. Huang, E. E. Deschner, H. L. Newmark, Z. Y. Wang, T. A. Ferraro, and A. H. Conney, Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett
64, 117–121 (1992).
25. M. T. Huang, H. L. Newmark, and K. Frenkel, Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem
27(Suppl), 26–34 (1997).
26. C. V. Rao, A. Rivenson, and B. S. Reddy, Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res
55, 259–266 (1995).
27. M. A. Pereira, C. J. Grubbs, L. H. Barnes, H. Li, G. R. Olson, I Eto, M. Juliana, L. M. Whitaker, G. J. Kelloff, V. E. Steele, and R. A. Lubet, Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis
17, 1305–1311 (1996).
28. T. Tanaka, H. Makita, M. Ohnishi, Y. Hirose, A. Wang, H. Mori, K. Satoh, A. Hara, and H. Ogawa, Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: Comparison with the protective effect of beta-carotene. Cancer Res
54, 4653–4659 (1994).
29. J. Ushida, S. Sugie, K. Kawabata, Q. V. Pham, T. Tanaka, K. Fujii, H. Takeuchi, Y. Ito, and H. Mori, Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res
91, 893–898 (2000).
30. M. A. Azuine and S. V. Bhide, Adjuvant chemoprevention of experimental cancer: Catechin and dietary turmeric in forestomach and oral cancer models. J Ethnopharmacol
44, 211–217 (1994).
31. N Li, X. Chen, J. Liao, G. Yang, S. Wang, Y. Josephson, C. Han, J. Chen, M. T. Huang, and C. S. Yang, Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis
23, 1307–1313 (2002).
32. S. Ikezaki, A. Nishikawa, F. Furukawa, K. Kudo, H. Nakamura, K. Tamura, and H. Mori, Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine and sodium chloride in rats. Anticancer Res
21, 3407–3411 (2001).
33. K. Singletary, C. MacDonald, M. Iovinelli, C. Fisher, and M. Wallig, Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene. Carcinogenesis
19, 1039–1043 (1998).
34. K. Singletary, C. MacDonald, M. Wallig, and C. Fisher, Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett
103, 137–141 (1996).
35. S. S. Hecht, P. M. Kenney, M. Wang, N Trushin, S. Agarwal, A. V. Rao, and P. Upadhyaya, Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett
137, 123–130 (1999).
36. N. Frank, J. Knauft, F. Amelung, J. Nair, H. Wesch, and H. Bartsch, No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat Res
523–524, 127–135 (2003).
37. J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med
1, 27–31 (1995).
38. C. Chen, S. Parangi, M. J. Tolentino, and J. Folkman, A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55, 4230–4233 (1995).
39. P. Yoysungnoen, P. Wirachwong, P. Bhattarakosol, H. Niimi, and S. Patumraj, Antiangiogenic activity of curcumin in hepatocellular carcinoma cells implanted nude mice. Clin Hemorheol Microcirc
33, 127–135 (2005).
40. Y. Ohashi, Y. Tsuchiya, K. Koizumi, H. Sakurai, and I. Saiki, Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology
65, 250–258 (2003).
41. J. H. Hong, K. S. Ahn, E. Bae, S. S. Jeon, and H. Y. Choi, The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis
9, 147–152 (2006)
42. T. Dorai, Y. C. Cao, B. Dorai, R. Buttyan, and A. E. Katz, Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate
47, 293–303 (2001).
43. B. B. Aggarwal, S. Shishodia, Y. Takada, S. Banerjee, R. A. Newman, C. E. Bueso-Ramos, and J. E. Price, Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res
11, 7490–7498 (2005).
44. L. G. Menon, R. Kuttan, and G. Kuttan, Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett
95, 221–225 (1995).
45. R. Kuttan, P. C. Sudheeran, and C. D. Josph, Turmeric and curcumin as topical agents in cancer therapy. Tumori
73, 29–31 (1987).
46. R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher, and W. P. Steward, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res
7, 1894–1900 (2001).
47. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher, and W. P. Steward, Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res
10, 6847–6854 (2004).
48. A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res
21, 2895–2900 (2001).
49. G. Garcea, D. P. Berry, D. J. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher, Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev
14, 120–125 (2005).
50. H. P. Ciolino, P. J. Daschner, T. T. Wang, and G. C. Yeh, Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol
56, 197–206 (1998).
51. R. Thapliyal and G. B. Maru, Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol
39, 541–547 (2001).
52. R. Thapliyal, S. S. Deshpande, and G. B. Maru, Effects of turmeric on the activities of benzo(a)pyrene-induced cytochrome P-450 isozymes. J Environ Pathol Toxicol Oncol
20, 59–63 (2001).
53. S. P. Valentine, M. J. Le Nedelec, A. R. Menzies, M. J. Scandlyn, M. G. Goodin, and R. J. Rosengren, Curcumin modulates drug metabolizing enzymes in the female Swiss Webster mouse. Life Sci
78, 2391–2398 (2005).
54. S. V. Singh, X. Hu, S. K. Srivastava, M. Singh, H. Xia, J. L. Orchard, and H. A. Zaren, Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis
19, 1357–1360 (1998).
55. M. Iqbal, S. D. Sharma, Y. Okazaki, M. Fujisawa, and S. Okada, Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol
92, 33–38 (2003).
56. S. B. Jones and J. D. Brooks, Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC Cancer
6, 62 (2006).
57. E. M. van der Logt, H. M. Roelofs, F. M. Nagengast, and W. H. Peters, Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis
24, 1651–1656 (2003).
58. S. J. McNally, E. M. Harrison, J. A. Ross, O. J. Garden, and S. J. Wigmore, Curcumin induces heme oxygenase-1 in hepatocytes and is protective in simulated cold preservation and warm reperfusion injury. Transplantation
81, 623–626 (2006).
59. E. Balogun, M. Hoque, P. Gong, E. Killeen, C. J. Green, R. Foresti, J. Alam, and R. Motterlini, Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J
371, 887–895 (2003).
60. R. Motterlini, R. Foresti, R. Bassi, and C. J. Green, Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radical Biol Med
28, 1303–1312 (2000).
61. N. Hill-Kapturczak, V. Thamilselvan, F. Liu, H. S. Nick, and A. Agarwal, Mechanism of heme oxygenase-1 gene induction by curcumin in human renal proximal tubule cells. Am J Physiol Renal Physiol
281, F851–F859 (2001).
62. M. T. Huang, T. Lysz, T. Ferraro, T. F. Abidi, J. D. Laskin, and A. H. Conney, Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res
51, 813–819 (1991).
63. F. Zhang, N. K. Altorki, J. R. Mestre, K. Subbaramaiah, and J. A. Dannenberg, Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis
20, 445–451 (1999).
64. S. M. Plummer, K. A. Holloway, M. M. Manson, R. J. Munks, A. Kaptein, S. Farrow, and L. Howells, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene
18, 6013–6020 (1999).
65. K. S. Chun, Y. S. Keum, S. S. Han, Y. S. Song, S. H. Kim, and Y.-J. Surh, Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis
24, 1515–1524 (2003).
66. G. Kang, P. J. Kong, Y. J. Yuh, S. Y. Lim, S. V. Yim, W. Chun, and S. S. Kim, Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappaB bindings in BV2 microglial cells. J Pharmacol Sci
94, 325–328 (2004).
67. I. Brouet and H. Ohshima, Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun
206, 533–540 (1995).
68. M. M. Chan, H. I. Huang, M. R. Fenton, and D. Fong, In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol
55, 1955–1962 (1998).
69. A. Duvoix, F. Morceau, M. Schnekenburger, S. Delhalle, M. M. Galteau, M. Dicato, and M. Diederich, Curcumin-induced cell death in two leukemia cell lines: K562 and Jurkat. Ann NY Acad Sci
1010, 389–392 (2003).
70. J. A. Bush, K. J. Cheung, Jr., and G. Li, Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res
271, 305–314 (2001).
71. N. R. Jana, P. Dikshit, A. Goswami, and N. Nukina, Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem
279, 11,680–11,685 (2004).
72. S. Aggarwal, H. Ichikawa, Y. Takada, S. K. Sandur, S. Shishodia, and B. B. Aggarwal, Curcumin (diferuloylmethane) down–regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol
69, 195–206 (2006).
73. J. H. Bae, J. W. Park, and T. K. Kwon, Ruthenium red, inhibitor of mitochondrial Ca2+ uniporter, inhibits curcumin-induced apoptosis via the prevention of intracellular Ca2+ depletion and cytochrome c release. Biochem Biophys Res Commun
303, 1073–1079 (2003).
74. J. H. Woo, Y. H. Kim, Y. J. Choi, D. G. Kim, K. S. Lee, J. H. Bae, S. Min do, J. S. Chang, Y. J. Jeong, Y. H. Lee, et al., Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis
24, 1199–1208 (2003).
75. A. Mukhopadhyay, C. Bueso-Ramos, D. Chatterjee, P. Pantazis, and B. B. Aggarwal, Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene
20, 7597–7609 (2001).
76. Y. Wu, Y. Chen, and M. He, The influence of curcumin on the cell cycle of HL-60 cells and contrast study. J Tongji Med Univ
20, 123–125 (2000).
77. A. Simon, D. P. Allais, J. L. Duroux, J. P. Basly, S. Durand-Fontanier, and C. Delage, Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure–activity relationships. Cancer Lett
129, 111–116 (1998).
78. R. Hanif, L. Qiao, S. J. Shiff, and B. Rigas, Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med
130, 576–584 (1997).
79. H. Chen, Z. S. Zhang, Y. L. Zhang, and D. Y. Zhou, Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res
19, 3675–3680 (1999).
80. L. Moragoda, R. Jaszewski, and A. P. Majumdar, Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res
21, 873–878 (2001).
81. M. J. Park, E. H. Kim, I. C. Park, H. C. Lee, S. H. Woo, J. Y. Lee, Y. J. Hong, C. H. Rhee, S. H. Choi, B. S. Shim, et al., Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol
21, 379–383 (2002).
82. A. E. Gururaj, M. Belakavadi, D. A Venkatesh, D. Marme, and B. P. Salimath, Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun
297, 934–942 (2002).
83. W. H. Chen, Y. Chen, and G. H. Cui, Effects of TNF-alpha and curcumin on the expression of VEGF in Raji and U937 cells and on angiogenesis in ECV304 cells. Chin Med J (Engl)
118, 2052–2057 (2005).
84. Z. M. Shao, Z. Z. Shen, C. H. Liu, M. R. Sartippour, V. L. Go, D. Heber, and M. Nguyen, Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer
98, 234–240 (2002).
85. J. S. Shim, J. H. Kim, H. Y. Cho, Y. N. Yum, S. H. Kim, H. J. Park, B. S. Shim, S. H. Choi, and H. J. Kwon, Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol
10, 695–704 (2003).
86. A. Banerji, J. Chakrabarti, A. Mitra, and A. Chatterjee, Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett
211, 235–242 (2004).
87. L. I. Lin, Y. F. Ke, Y. C. Ko, and J. K. Lin, Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology
55, 349–353 (1998).
88. K. W. Lee, J. H. Kim, H. J. Lee, and Y. J. Surh, Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal
7, 1612–1620 (2005).
89. M. S. Woo, S. H. Jung, S. Y. Kim, J. W. Hyun, K. H. Ko, W. K. Kim, and H. S. Kim, Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun
335, 1017–1025 (2005).
90. S. S. Kakar and D. Roy, Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett
87, 85–89 (1994).
91. P. Limtrakul, S. Anuchapreeda, S. Lipigorngoson, and F. W. Dunn, Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer
1, 1 (2001).
92. Y. P. Lu, R. L. Chang, Y. R. Lou, M. T. Huang, H. L. Newmark, K. R. Reuhl, and A. H. Conney, Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis. Carcinogenesis
15, 2363–2370 (1994).
93. S. S. Han, S. T. Chung, D. A. Robertson, D. Ranjan, and S. Bondada, Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kB, and p53. Clin Immunol
93, 152–161 (1999).
94. A. S. Jaiswal, B. P. Marlow, N. Gupta, and S. Narayan, Beta-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene
21, 8414–8427 (2002).
95. D. Bech-Otschir, R. Kraft, X. Huang, P. Henklein, B. Kapelari, C. Pollmann, and W. Dubiel, COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J
20, 1630–1639 (2001).
96. T. Choudhuri, S. Pal, M. L. Agwarwal, T. Das, and G. Sa, Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett
512, 334–340 (2002).
97. A. Liontas and H. Yeger, Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res
24, 987–998 (2004).
98. M. Shi, Q. Cai, L. Yao, Y. Mao, Y. Ming, and G. Ouyang, Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int
30, 221–226 (2006).
99. G. Song, Y. B. Mao, Q. F. Cai, L. M. Yao, G. L. Ouyang, and S. D. Bao, Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res
38, 1791–1798 (2005).
100. T. Prestera and P. Talalay, Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA
92, 8965–8969 (1995).
101. E. A. Chiocca and D. J. Waxman, Cytochrome P450-based gene therapies for cancer. Methods Mol Med
90, 203–222 (2004).
102. S. S. Deshpande and G. B. Maru, Effects of curcumin on the formation of benzo[a]pyrene derived DNA adducts in vitro. Cancer Lett
96, 71–80 (1995).
103. J. S. Lee and Y. J. Surh, Nrf2 as a novel molecular target for chemoprevention. Cancer Lett
224, 171–184 (2005).
104. S. Numazawa and T. Yoshida, Nrf2-dependent gene expressions: A molecular toxicological aspect. J Toxicol Sci
29, 81–89 (2004).
105. D. A. Dickinson, K. E. Iles, H. Zhang, V. Blank, and H. J. Forman, Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. FASEB J
17, 473–475 (2003).
106. Y.-J. Surh, K. S. Chun, H. H. Cha, S. S. Han, Y. S. Keum, K. K. Park, and S. S. Lee, Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappaB activation. Mutat Res
480–481, 243–268 (2001).
107. Y.-J. Surh, Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res
428, 305–327 (1999).
108. C. S. Divya and M. R. Pillai, Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkappaB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog
45, 320–332 (2006).
109. C. Jobin, C. A. Bradham, M. P. Russo, B. Juma, A. S. Narula, D. A. Brenner, and R. B. Sartor, Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity. J Immunol
163, 3474–3483 (1999).
110. M. Roy, S. Chakraborty, M. Siddiqi, and R. K. Bhattacharya, Induction of apoptosis in tumor cells by natural phenolic compounds. Asian Pacific J Cancer Prev
3, 61–67 (2002).
111. E. Tourkina, P. Gooz, J. C. Oates, A. Ludwicka-Bradley, R. M. Silver, and S. Hoffman, Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol
31, 28–35 (2004).
112. M. C. Jiang, H. F. Yang-Yen, J. J. Yen, and J. K. Lin, Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer
26, 111–120 (1996).
113. H. R. Stennicke and G. S. Salvesen, Biochemical characteristics of caspases-3, -6, -7, and -8. J Biol Chem
272, 25719–25723 (1997).
114. H. Sakahira, M. Enari, and S. Nagata, Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature
391, 96–99 (1998).
115. S. N. Farrowand R. Brown, New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev
6, 45–49 (1996).
116. R. A. Sharma, A. J. Gescher, and W. P. Steward, Curcumin: the story so far. Eur J Cancer
41, 1955–1968 (2005).
117. A. R. Hussain, M. Al-Rasheed, P. S. Manogaran, K. A. Al-Hussein, L. C. Platanias, K. A. Kuraya, and S. Uddin, Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis
11, 245–254 (2006).
118. A. Chen and J. Xu, Activation of PPAR′ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol
288, G447–G456 (2005).
119. J. S. Shim, J. Lee, H. H. Park, S. J. Park, and H. J. Kwon, A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem Biol
11, 1455–1463 (2004).
120. J. L. Arbiser, N. Klauber, R. Rohan, R. van Leeuwen, M. T. Huang, C. Fisher, E. Flynn, and H. R. Byers, Curcumin is an in vivo inhibitor of angiogenesis. Mol Med
4, 376–383 (1998).
121. L. A. Liotta and W. G. Stetler-Stevenson, Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res
51, 5054s–5059s (1991).
122. A. John and G. Tuszynski, The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res
7, 14–23 (2001).
123. M. Egeblad and Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer
2, 161–174 (2002).
124. S. Ray, N. Chattopadhyay, A. Mitra, M. Siddiqi, and A. Chatterjee, Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol
22, 49–58 (2003).
125. J. H. Kim, J. S. Shim, S. K. Lee, K. W. Kim, S. Y. Rha, H. C. Chung, and H J. Kwon, Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res
93, 1378–1385 (2002).
126. J. L. Bos, Ras oncogenes in human cancer: A review. Cancer Res
49, 4682–4689 (1989).
127. G. F. Claassen and S. R. Hann, Myc-mediated transformation: the repression connection. Oncogene
18, 2925–2933 (1999).
128. S. Adhikary and M. Eilers, Transcriptional regulation and transformation by Myc proteins. Nature Rev Mol Cell
6, 635–645 (2005).
129. T. Tokino and Y. Nakamura, The role of p53-target genes in human cancer. Crit Rev Oncol Hematol
33, 1–6 (2000).
130. T. Choudhuri, S. Pal, T. Das, and G. Sa, Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem
280, 20059–20068 (2005).
131. P. J. Moos, K. Edes, J. E. Mullally, and F. A. Fitzpatrick, Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis
25, 1611–1617 (2004).
132. P. Tsvetkov, G. Asher, V. Reiss, Y. Shaul, L Sachs, and J. Lotem, Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA
102, 5535–5540 (2005).